Wednesday, June 17, 12:30 – 2:00 pm
Auditorium Condé

Chairs: Manfred Lutz (Germany) – Ines Gockel (Switzerland) – Sara Lonardi (Italy) – Jean-Philippe Metges (France)

1. HER2-Targeted Therapies:  new upcoming trials. – Alberto Puccini (Italy)
2. Role of Immunotherapy for long-term survivorship. – Markus Moehler (Germany) 
3. Claudin 18.2 Therapies for Gastroesophageal Cancer: full remission possible? – Jean-Philippe Metges (France)
4. Thinking out of the box with localized disease or TNT. – Ines Gockel (Switzerland)
5. CtDNA guidance? PLAGAST and more. – Catherine Streutker (Canada)
6. When de-escalation after first line? – Sara Lonardi (Italy) 
7. Liver limited disease: resect metastases like in colon cancer? – Beat Müller (Switzerland) 
8. Oral Abstract Presentation: Comparative Outcomes of Neoadjuvant Immunochemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Cancer: A Real-World Study. – Zhiyu Li (China)
9. Oral Abstract Presentation: Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study. – Yuquan Bai (China) 
10. Final discussion: Next challenges in esophageal cancer: ALL participants